Tuesday, October 06, 2026
During the keynote at ARM’s Meeting on the Mesa, Karim Mikhail, recently selected to lead CBER after serving as the center’s acting director, offered a candid look at the challenges regulators face in accelerating the development of innovative cell and gene therapies for rare diseases.